CDH26: A Potential Drug Target for Cancer and Tissue Repair (G60437)

Target Name: CDH26

NCBI ID: G60437

CDH26

CDH26: A Potential Drug Target for Cancer and Tissue Repair

Cadherins are a family of transmembrane proteins that play a crucial role in cell-cell adhesion. CDH26, also known as Cadherin 26, is a member of the cadherin family and is expressed in various tissues throughout the body. It is known to be involved in many different processes in the body, including cell signaling, tissue repair, and cancer progression.

CDH26 has been identified as a potential drug target and has been the subject of intense research in recent years. In this article, we will explore the biology of CDH26 and its potential as a drug target.

biology and functions

CDH26 is a 26kDa transmembrane protein that is expressed in various tissues, including epithelial, muscle, heart, and brain cells. It is a member of the cadherin family and is characterized by the presence of a transmembrane domain and a cytoplasmic tail.

CDH26 is involved in many different processes in the body, including:

1. Cell signaling: CDH26 is a key component of the cadherin signaling pathway, which is involved in the regulation of cell signaling pathways. It plays a role in the development and maintenance of tight junctions, which are a type of cell-cell adhesion that is critical for proper tissue structure and function.
2. Tissue repair: CDH26 is also involved in tissue repair and regeneration. It has been shown to be involved in the regulation of cell proliferation and the formation of new tissues during wound healing.
3. Cancer progression: CDH26 has also been linked to cancer progression. It has been shown to be involved in the development and metastasis of various cancers, including breast, ovarian, and prostate cancers.

CDH26 is also a potent drug target and has been shown to be involved in a wide range of drug-related processes, including:

1. Cell adhesion: CDH26 is involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs. It has been shown to be involved in the regulation of cell-cell adhesion, as well as cell-cell junctions.
2. Signal transduction: CDH26 is involved in the regulation of signal transduction, which is the process by which cells respond to signals from the environment. It has been shown to be involved in the regulation of intracellular signaling pathways, including the TGF-β pathway.
3. Oncology: CDH26 has also been shown to be involved in the development and progression of various cancers, including breast, ovarian, and prostate cancers. It has been shown to be involved in the regulation of cell proliferation, angiogenesis, and drug resistance.

CDH26 has also been shown to have a number of potential drug-like compounds that have been shown to be inhibitors of its activity. These compounds have been shown to be effective in a wide range of therapeutic applications, including the treatment of various cancers.

drug targeting

CDH26 is a highly promising drug target, and a number of studies have been conducted to investigate its potential as a drug. One of the main strategies being explored is the use of small molecules and other compounds that can inhibit the activity of CDH26.

Several studies have shown that inhibitors of CDH26, such as inhibitors of its tyrosine kinase activity, can be effective in a wide range of therapeutic applications, including the treatment of various cancers. These compounds have been shown to be effective in both preclinical and clinical settings, and further studies are being conducted to determine their safety and efficacy.

Another approach being explored is the use of antibodies that can specifically target CDH26 and inhibit its activity. These antibodies have been shown to be effective in preclinical settings and are being

Protein Name: Cadherin 26

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. Ligand for integrins alpha-E/beta-7, ITGAE:ITGAB7, alpha-4/beta-7, ITGA4:ITGAB7 and alpha-4/beta-1, ITGA4:ITGAB1 through which modulates CD4(+) T cells activation (PubMed:28051089)

The "CDH26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH26 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets